# A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

> **NCT06113471** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 450 (actual)

## Conditions studied

- NonSegmental Vitiligo

## Interventions

- **DRUG:** Povorcitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06113471
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-27
- **Primary completion:** 2026-03-17
- **Final completion:** 2027-03-16
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113471, "A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06113471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*